Off-label Use

The FDA approves specific prescription medications for specific uses based on the data submitted in the New Drug Application (NDA). The approved label specifies the indication, dose, route, contraindications, and population. The label is a legal document that pharmacists, prescribers, and patients rely on for predictable drug behavior.

Off-label use refers to any prescription that deviates from the approved label. Common categories include:

- Prescribing the medication for a different disease (e.g., gabapentin for diabetic neuropathy was off-label before being approved). - Prescribing at a dose outside the labeled range. - Prescribing for a different age group (e.g., adult medications for pediatric use). - Prescribing through a different route (e.g., topical application of a medication only labeled for oral use).

Off-label prescribing is legal in the United States and is widespread in many specialties. Examples in this site's clinical scope include low-dose oral minoxidil for hair loss, dutasteride for hair loss, low-dose tadalafil for daily ED dosing in some scenarios, low-dose rapamycin for longevity, and enclomiphene for secondary hypogonadism in men.

The legal status does not mean the off-label use is well-studied. Some off-label uses (low-dose oral minoxidil) have growing peer-reviewed evidence; others (some peptide protocols) extrapolate from preclinical or small clinical data.

Patients considering an off-label prescription should ask the clinician what evidence supports the use, what is unknown, what monitoring is appropriate, and what the alternatives are. Off-label use should be discussed with your clinician.

Off-label use is distinct from compounded medications and from "research peptides." Off-label refers to the use of an FDA-approved product. Compounded medications are non-approved preparations. Research peptides are unregulated chemicals sold outside the regulated drug supply.